Morgan Stanley Raises Olaplex Price Target to $2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy OLPX?
Morgan Stanley analyst Dara Mohsenian raised the firm's price target on Olaplex (OLPX) to $2 from $1.40 and keeps an Equal Weight rating on the shares after the company agreed to be acquired by Heinkel (HENKY) for $1.4B. The firm does not expect a competing bid given the deal potential has been outlined in press reports, which should have drawn out other interest. Olaplex's turnaround strategy is focused in driving core products, increased marketing, and a stronger innovation pipeline, and Olaplex will add to Henkel's hair care portfolio, the analyst tells investors in a research note.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OLPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OLPX
Wall Street analysts forecast OLPX stock price to fall
7 Analyst Rating
2 Buy
4 Hold
1 Sell
Hold
Current: 2.040
Low
1.25
Averages
1.98
High
4.00
Current: 2.040
Low
1.25
Averages
1.98
High
4.00
About OLPX
Olaplex Holdings, Inc. is a foundational health and beauty company. Its Complete Bond Technology works by protecting, strengthening and relinking all three bonds during and after hair services. Its product portfolio includes 23 products that support the hair health needs of its professional hairstylist and consumer communities. It developed its patent-protected bond-building technology, Bis-amino, which works on the molecular level to repair the hair’s disulfide bonds. Leveraging its Bis-amino technology, its two-part salon and at home bond-building treatments are complete bond builders that can repair all three main chemical bonds deep inside the hair: hydrogen, ionic and disulfide bonds. Its OLAPLEX Bond Shaping Technology is a proprietary peptide that penetrates deep into the hair to strengthen, rebuild, and reform curl-shaping disulfide bonds. Its products are sold globally through an omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Affinity Bancshares, Inc. and Fidelity Bancshares, where Affinity shareholders are expected to receive $23.00 per share in cash, significantly impacting shareholder returns.
- Apellis Pharmaceutical Deal: In the transaction between Apellis Pharmaceuticals, Inc. and Biogen, Apellis shareholders are expected to receive $41.00 per share in cash along with two non-transferable rights of $2.00 each, providing additional potential earnings and enhancing investment appeal.
- Olaplex Acquisition Case: In the deal between Olaplex Holdings, Inc. and Henkel US Operations, Olaplex shareholders are expected to receive $2.06 per share in cash, offering direct cash returns to shareholders and boosting market confidence.
- KORE Group Transaction: In the transaction involving KORE Group Holdings, Inc. and Searchlight Capital Partners, KORE shareholders are expected to receive $9.25 per share in cash, providing substantial cash flow to shareholders and further solidifying their market position.
See More
Investigation into Olaplex's Transaction with Henkel for Possible Legal Violations
- Transaction Value: The deal between Olaplex and Henkel is valued at approximately $1.4 billion, with shareholders set to receive $2.06 per share in cash, which could impact the company's future financial stability.
- Board Accountability: The investigation focuses on whether the Olaplex board is fulfilling its fiduciary duties to all shareholders, particularly regarding potential conflicts of interest in the transaction that could harm shareholder rights.
- Competition Limitation Clause: The transaction agreement includes clauses that restrict competing bids, imposing significant penalties if Olaplex accepts another offer, which may deter other potential acquirers and affect the company's valuation.
- Legal Litigation Risks: Ademi LLP specializes in shareholder litigation and may challenge Olaplex's transaction legally; if violations are found during the investigation, the company could face legal liabilities and financial repercussions.
See More
Monteverde Law Firm Investigates Mergers for Shareholder Recovery
- Merger Investigation: Monteverde & Associates is investigating the merger between Corebridge Financial and Equitable Holdings, with Corebridge shareholders expected to own approximately 51% of the combined entity, indicating significant implications for shareholder equity post-merger.
- Olaplex Shareholder Payout: Under the proposed sale to Henkel US Operations, Olaplex Holdings shareholders are anticipated to receive $2.06 per share in cash, providing a direct financial benefit to shareholders amidst the transaction.
- FONAR Stock Buyback: FONAR Corporation's shareholders will receive $19.00 per share for Class B common stock and $6.34 per share for Class C common stock as part of the transaction with company executives, offering substantial returns to stockholders.
- Coterra Energy Transaction: In the deal with Devon Energy, Coterra shareholders will receive 0.70 shares of Devon common stock for each share of Coterra common stock, which is expected to alter the shareholder structure and potentially impact future shareholder value.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Olaplex Stock Surpasses Analyst Target Price
- Stock Performance: Olaplex Holdings Inc's shares have surpassed the average analyst 12-month target price of $1.84, currently trading at $2.01, indicating market optimism regarding the company's future prospects.
- Analyst Reactions: When a stock reaches an analyst's target price, they may either downgrade on valuation or raise the target, reflecting the market's focus on fundamental changes at Olaplex, which could influence investor decisions.
- Target Price Distribution: Among the 8 analysts covered by Zacks, target prices range from $1.40 to $2.50, with a standard deviation of $0.367, highlighting differing views on Olaplex's future performance, necessitating careful investor assessment.
- Investor Signal: The stock's rise above the target price provides a good signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it might be time to take profits.
See More
Olaplex Acquired by Henkel for $2.06 per Share
- Acquisition Deal: German consumer goods giant Henkel has agreed to acquire Olaplex for $2.06 per share in cash, totaling $1.4 billion, marking the end of Olaplex's disappointing run as a public company.
- Stock Surge: Following the announcement, Olaplex's stock surged by 51.13% to close at $2.01, with trading volume reaching 104.6 million shares, approximately 2,904% above its three-month average, indicating strong market reaction to the acquisition.
- Market Performance: Since its IPO in 2021, Olaplex's stock has plummeted by 92%, and this acquisition provides much-needed liquidity, potentially offering investors a timely exit opportunity.
- Industry Consolidation: Olaplex's niche products may find better synergy within Henkel's brand portfolio, and the acquisition could help Henkel expand its influence in the personal care market while providing Olaplex with stronger market support.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Affinity Bancshares, Inc. and Fidelity Bancshares, where Affinity shareholders are expected to receive $23.00 per share in cash, significantly impacting shareholder returns.
- Apellis Pharmaceutical Deal: In the transaction between Apellis Pharmaceuticals, Inc. and Biogen, Apellis shareholders are expected to receive $41.00 per share in cash along with two non-transferable rights of $2.00 each, providing additional potential earnings and enhancing investment appeal.
- Olaplex Acquisition Case: In the deal between Olaplex Holdings, Inc. and Henkel US Operations, Olaplex shareholders are expected to receive $2.06 per share in cash, offering direct cash returns to shareholders and boosting market confidence.
- KORE Group Transaction: In the transaction involving KORE Group Holdings, Inc. and Searchlight Capital Partners, KORE shareholders are expected to receive $9.25 per share in cash, providing substantial cash flow to shareholders and further solidifying their market position.
See More
Investigation into Olaplex's Transaction with Henkel for Possible Legal Violations
- Transaction Value: The deal between Olaplex and Henkel is valued at approximately $1.4 billion, with shareholders set to receive $2.06 per share in cash, which could impact the company's future financial stability.
- Board Accountability: The investigation focuses on whether the Olaplex board is fulfilling its fiduciary duties to all shareholders, particularly regarding potential conflicts of interest in the transaction that could harm shareholder rights.
- Competition Limitation Clause: The transaction agreement includes clauses that restrict competing bids, imposing significant penalties if Olaplex accepts another offer, which may deter other potential acquirers and affect the company's valuation.
- Legal Litigation Risks: Ademi LLP specializes in shareholder litigation and may challenge Olaplex's transaction legally; if violations are found during the investigation, the company could face legal liabilities and financial repercussions.
See More
Monteverde Law Firm Investigates Mergers for Shareholder Recovery
- Merger Investigation: Monteverde & Associates is investigating the merger between Corebridge Financial and Equitable Holdings, with Corebridge shareholders expected to own approximately 51% of the combined entity, indicating significant implications for shareholder equity post-merger.
- Olaplex Shareholder Payout: Under the proposed sale to Henkel US Operations, Olaplex Holdings shareholders are anticipated to receive $2.06 per share in cash, providing a direct financial benefit to shareholders amidst the transaction.
- FONAR Stock Buyback: FONAR Corporation's shareholders will receive $19.00 per share for Class B common stock and $6.34 per share for Class C common stock as part of the transaction with company executives, offering substantial returns to stockholders.
- Coterra Energy Transaction: In the deal with Devon Energy, Coterra shareholders will receive 0.70 shares of Devon common stock for each share of Coterra common stock, which is expected to alter the shareholder structure and potentially impact future shareholder value.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Olaplex Stock Surpasses Analyst Target Price
- Stock Performance: Olaplex Holdings Inc's shares have surpassed the average analyst 12-month target price of $1.84, currently trading at $2.01, indicating market optimism regarding the company's future prospects.
- Analyst Reactions: When a stock reaches an analyst's target price, they may either downgrade on valuation or raise the target, reflecting the market's focus on fundamental changes at Olaplex, which could influence investor decisions.
- Target Price Distribution: Among the 8 analysts covered by Zacks, target prices range from $1.40 to $2.50, with a standard deviation of $0.367, highlighting differing views on Olaplex's future performance, necessitating careful investor assessment.
- Investor Signal: The stock's rise above the target price provides a good signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it might be time to take profits.
See More
Olaplex Acquired by Henkel for $2.06 per Share
- Acquisition Deal: German consumer goods giant Henkel has agreed to acquire Olaplex for $2.06 per share in cash, totaling $1.4 billion, marking the end of Olaplex's disappointing run as a public company.
- Stock Surge: Following the announcement, Olaplex's stock surged by 51.13% to close at $2.01, with trading volume reaching 104.6 million shares, approximately 2,904% above its three-month average, indicating strong market reaction to the acquisition.
- Market Performance: Since its IPO in 2021, Olaplex's stock has plummeted by 92%, and this acquisition provides much-needed liquidity, potentially offering investors a timely exit opportunity.
- Industry Consolidation: Olaplex's niche products may find better synergy within Henkel's brand portfolio, and the acquisition could help Henkel expand its influence in the personal care market while providing Olaplex with stronger market support.
See More
